IPCA Laboratories has been granted a patent for a modified lectin protein with specific amino acid modifications, excluding certain sequences. The protein’s amino acid sequence is chosen from SEQ ID NOs: 5 and 14. GlobalData’s report on IPCA Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on IPCA Laboratories, Peptide pharmacophores was a key innovation area identified from patents. IPCA Laboratories's grant share as of May 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11965003B2) discloses a modified lectin protein designed for the treatment of cancer. The modified lectin protein, with specific amino acid sequences, is utilized in a pharmaceutical composition along with other therapeutic ingredients and a pharmaceutically acceptable diluent or excipient. This composition is then administered to patients for the treatment of cancer, offering a novel approach to combating the disease.
Moreover, the patent claims cover various methods related to cancer treatment, including detecting cancer cells, diagnosing cancer, and providing therapy for cancer by utilizing the modified lectin protein. The patent also includes details on the nucleic acid molecule encoding the modified lectin protein, recombinant vectors for its production, and transformed host cells for expression. The method for producing the recombinant modified lectin protein involves culturing a host cell containing the recombinant vector, expressing the protein, and isolating it from the culture. These claims highlight the potential of the modified lectin protein in revolutionizing cancer treatment through innovative therapeutic approaches.
To know more about GlobalData’s detailed insights on IPCA Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
